Sernova Corp (TSX:SVA)

C$ 0.37 0.02 (5.71%) Market Cap: 112.34 Mil Enterprise Value: 104.47 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 30/100

Sernova Corp Business Update, Strategy and Outlook Call Transcript
Oct 05, 2023
Sernova Corp Introduction of the New CEO and Recently Appointed Chief Business Officer Call Transcript
Sep 22, 2023
Sernova Corp Cell & Gene Meeting on the Med 2023 Transcript
Jun 01, 2023
Sernova Corp at Oppenheimer Healthcare Conference (Virtual) Transcript
Mar 14, 2023
Sernova Corp at ROTH Conference Transcript
Mar 13, 2023
Sernova Corp To Discuss on Regenerative Therapeutics to Develop Functional Cures Transcript
Oct 11, 2022
Sernova Corp at H C Wainwright Global Investment Conference (Virtual) Transcript
Sep 13, 2022
Evotec SE and Sernova Corp to Discuss Exclusive Strategic Partnership M&A Call Transcript
May 17, 2022
Sernova Corp CEO Roadshow Transcript
Dec 10, 2020
Sernova Corp At TSX Life Sciences Investor Day Transcript
Oct 30, 2020
Sernova Corp at Alliance for Regenerative Medicine Cell & Gene Meeting on the Mesa (Virtual) Transcript
Oct 13, 2020
Sernova Corp At ADA Scientific Sessions Transcript
Jun 13, 2020
Sernova Corp At CEO Conference Call Transcript
May 29, 2020

Sernova Corp at Alliance for Regenerative Medicine Cell & Gene Meeting on the Mesa (Virtual) Transcript

Oct 13, 2020 / 07:00PM GMT

Release Date Price: C$0.305

Transcript

Philip Toleikis

Sernova Corp. - President, CEO

Hello, everyone. Welcome to the Sernova Corp presentation. My name is Dr. Philip Toleikis, President and CEO of Sernova Corp. And I just want to show my appreciation for being invited to the Cell & Gene Meeting on the Mesa in 2020. Today, I'm going to go over Sernova Corp, and in terms of our regenerative medicine approach, and update everyone on our clinical trials as we're looking forward.

So Sernova itself is an innovator and a leader in this field. We've been working on the cell therapy approach for therapeutics for over 11 years and we are now in clinical trials, and I'm going to show you some of the successes that we've had with our therapeutic cell and device approach. We are working both on diabetes program, and we also have the hemophilia A, and thyroid preclinical programs for which well we have validated our technology in.

Sernova's approach takes three types of applications here. So first, we've developed what we call a cell pouch, and the cell pouch technology is highly scalable. And this is an implantable device. It is

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.